Abstract:
30 31 Implants for the treatment of tissue defects should mimic the mechanical properties of the native 32 tissue of interest and should be resorbable as well as biocompatible. In this work, we developed 33 a scaffold from variants of poly-L-glycolic acid which were braided and coated with an elastomer 34 of poly(glycolide-co-caprolactone) and crosslinked. The coating of the scaffold with the elastomer 35 led to higher mechanical strength in terms of compression, expansion and elasticity compared to 36 braids without the elastomer coating. These composite scaffolds were found to have expansion 37
properties similar to metallic stents, utilizing materials which are typically much weaker than metal. 38 We optimized the mechanical properties of the implant by tuning the elastomer branching 39 structure, crosslink density, and molecular weight. The scaffolds were shown to be highly 40 resorbable following implantation in a porcine femoral artery. Biocompatibility was studied in vivo 41 in an ovine model by implanting the scaffolds into femoral arteries. The scaffolds were able to 42
support an expanded open lumen over 12 months in vivo and also fully resorbed by 18 months in 43 the ovine model. 44
Many soft tissues in the body undergo significant motion or experience substantial 45 pressure. Strong, elastic, bioresorbable implants could be useful in cartilage repair, vascular 46 grafts, sinusitis treatment, and treatment of pediatric conditions. A major limitation of medical 47 implants used to treat these tissues is the lack of materials that mimic the strength and elasticity 48 of the native tissue. Beyond the mechanical properties, an ideal medical implant would also be 49 resorbable, to provide utility only until the native tissue has healed. 50
To illustrate the capability of our scaffold, we focused on arterial disease where strong, 51 bioresorbable materials have been touted as the wave of the future [1] [2] [3] [4] . Here, bioresorbable 52 scaffolds provide temporary strength -holding a vessel at an expanded diameter and resisting 53 vessel recoil only until healing has occurredwhile eliminating a permanent foreign body. Balloon 54 expandable, polymeric, bioresorbable scaffolds are fabricated from monolithic, highly-crystalline, 55 oriented, extruded tubes of polymers to achieve the necessary mechanical properties [1, 4, 5] . 56 While such scaffolds have found applications in coronary arteries, these devices would fail in 57 patients with peripheral arterial disease, whereby the vessels (such as the superficial femoral 58 artery) undergo significant motion resulting in kinking and fracturing of the stiff devices. As a result, 59 vessels with significant motion are currently treated using self-expanding metal devices, which 60
have the required strength to resist vessel recoil and are designed with elasticity and flexibility to 61 withstand the forces resulting from vessel motion. Despite this, self-expanding metal devices have 62 high fracture rates associated with stent restenosis that significantly lowers vessel patency [6] . 63
An ideal stent in vessels experiencing significant motion would couple the benefits of self-64 expanding metal devices (strength and elasticity of native tissue) with those of bioresorbable 65 devices (no permanent foreign body). Currently, no such device exists. The key challenge in 66 creating any self-expanding implant is the need for the implant to be strong, elastic, and 67
biocompatible. Designing a self-expanding device that is also bioresorbable is particularly 68 challenging due to the limited strength of available materials. For example, "strong" bioresorbable 69 polymers have tensile properties that are only one-tenth those of the metals used in existing self-70 expanding devices. This design challenge is further complicated by the environment of the 71 vasculature, where materials have elicited higher inflammatory responses relative to other body 72 locations [7] [8] [9] [10] [11] . A final design complexity is that commonly used bioresorbable polymers are 73 prone to stress relaxation. That is, when the device is crimped into a catheter for delivery to the 74 target vessel, the strain on the device can lead to permanent deformation. 75
We hypothesized that we could create a self-expanding, bioresorbable implant utilizing a 76 unique composite design. This design would consist of fiber braid (strong, highly oriented fibers 77 in a design that enables bending) coated with an elastomer. The thermoset elastomer would be 78 cured on the braid at the fully-expanded diameter to provide a mechanism for the implant to 79 "spring back" or self-expand to its fabricated diameter by constraining the points of intersection of 80 the braid. Utilizing this composite design, we have created an implant with radial force properties 81 equivalent to metal, using "weak" polymeric materials that fully resorb. 82
Benchmark self-expanding designs and the limitations of polymeric materials 83
Our initial design efforts for a bioresorbable polymer implant focused on braiding fibers 84 from commercially available "strong" materials, such as poly(glycolide) (PGA) and poly(L-lactide) 85
(L-PLA). These fibers were extruded and annealed to maximize the crystallinity and polymer 86 orientation, in order to maximize the modulus of the materials. Despite these processing efforts, 87 the PGA, L-PLA, and their copolymer poly(L-lactide-co-glycolide) (L-PLGA) fibers had 88 significantly less mechanical stiffness than the stainless steel or nickel titanium (NiTi) materials 89 that are used to manufacture two benchmark self-expanding metal stent devices ( Figure 1A) [12]. 90
The Wallstent® (Boston Scientific Corporation) utilizes stainless steel wires in a braided design, 91
imparting flexibility and elasticity on this stiff, inelastic material (e.g. 316L stainless steel has a 92 tensile modulus = 200GPa, elongation-to-break < 1%) while S.M.A.R.T® (Cordis Corporation) 93 stent is fabricated from super-elastic metals, such as nickel titanium (NiTi), that possesses both 94 stiff and elastic material properties (e.g. NiTi used in S.M.A.R.T® stent has tensile modulus = 40-95 75GPa, elongation-to-break = 10-15%). These differing approaches have resulted in stent 96 designs with a range of mechanical properties. The radial stiffness (RRF), a measure of the stent's 97 ability to withstand compression from a vessel, for the S.M.A.R.T. ® and Wallstent® stents are 98 411 and 140 mmHg, respectively; the chronic outward force (COF), a measure of a stent's ability 99
to expand the vessel wall, for the S.M.A.R.T. ® and Wallstent® stents are 208 mmHg and 68 100 mmHg, respectively ( Figure 1B ). These metal devices also recover fully to their initial diameter 101 after deployment, as there is no stress relaxation leading to plastic deformation. 102
Base braid designs fabricated from optimally processed PLGA fibers had insufficient 103 mechanical properties when compared to the above benchmark devices, consistent with the 104 observations of others ( Figure 1B) [13]. In addition to the weak mechanical properties, stress 105 relaxation was also observed when performing simulated deployments of the base braid. That is, 106 the process of crimping the base braid to a 7French catheter to enable delivery to the target vessel 107 and then expanding the device 10 minutes later led to significant stress relaxation of the polymers 108 and permanent deformation of the deviceresulting in a 25% reduction in the diameter of the 109 braid, consistent with the results of others [14, 15] . We hypothesized that a successful 110 bioresorbable, self-expanding implant should have mechanical properties similar to these 111 benchmark metal devices. 112
Design and optimization of the elastomer 113
To impart desired mechanical properties to the base braid, we developed a bioresorbable 114 elastomer material (that would be used to coat the base braid). We hypothesized that the 115 combination of the fibers comprising the base braid, coupled with an overlying elastomer coating 116 that constrains the intersection points of the braid (Figure 2A -C) would result in an implant with 117 the ability to self-expand into a flexible, elastic structure with high radial stiffness ( Figure 2D , E). 118
Sufficient elasticity of the coating would be required to withstand the range of diameters 119 experienced during the crimping and deployment process (e.g., manufactured diameter ~7mm  120 diameter in catheter ~1.9mm  expanded diameter in vessel ~6mm). 121
We developed the elastomer leveraging well-characterized, biocompatible materials from 122 the PLA, PGA, and polycaprolactone (PCL) families. These materials degrade via hydrolysis into 123 metabolites that can be safely eliminated from the body [16] . Because of this safe route of 124 elimination, these materials have been widely used in the body as sutures, orthopedic tissue 125 fixation devices, and drug delivery systems [17] . Additionally, this class of polymers provides the 126 ability to modulate the mechanical properties and absorption profile by combining the monomers 127 at various compositions [18] . 128
The glass transition temperature (Tg) of an elastomer is critical in determining its elasticity. 129
To ensure that the elastomer is not in the glassy state during crimping or deployment, its Tg must 130 be less than room and body temperature. This requirement necessitated incorporation of -131 caprolactone into the elastomer, due to the low Tg of its polymers (-60ºC); in contrast, the Tg of 132 lactide and glycolide polymers is above body temperature. However, homopolymers of -133 caprolactone are highly crystalline and prone to permanent deformation. Therefore, in addition to 134 -caprolactone, we also selected glycolide and lactide as the building blocks of our initial 135 elastomer to provide a fast resorbing, highly elastic material. 136
Initial elastomers were synthesized as linear pre-polymers of poly(glycolide-co-137 caprolactone) (PGCL). We prepared films from this prepolymer and characterized their 138 mechanical properties. This elastomer demonstrated a high elongation-to-break, although it was 139 prone to high plastic deformation. As a result, when the stretched elastomer was released it would 140 not recover to its original dimensions. We hypothesized this deformation was due to irreversible 141 alignment of polymer chains under tensile forces. To decrease this deformation, we incorporated 142 a four-arm branched initiator, pentaerythritol, into the reaction to create a four-arm branched 143 prepolymer of PGCL ( Figure 2F ). The four-arm structure provided "crosslink" points in the 144 prepolymer, helping to overcome plastic deformation and providing mechanical strength to the 145 elastomer. Elasticity and deformation of the elastomer were further optimized by controlling the 146 crosslink density of the elastomer. A tightly crosslinked elastomer, while strong, yielded a low 147 elongation-to-break. In contrast, a loosely crosslinked system behaved similarly to the non-148 crosslinked linear polymer; it had high elongation-to-break but was prone to plastic deformation. 149 Figure 3A illustrates the mechanical properties of two, four arm PGCL cross linked elastomers 150 prepared: one with low elongation-to-break and one with high elongation-to-break. The molecular 151 weights of the prepolymers for these elastomers are 20,000 and 40,000 g/mol, respectively, and 152 both elastomers were fabricated at a prepolymer-to-hexamethylene diisocyanate (HDI) ratio of 153 8:1 (wt/wt). Figure 3B and C show the morphology of base braids coated with these elastomers 154 after they have been crimped and deployed from a 7French catheter. The low elongation-to-break 155 elastomer coated implants results in visible cracking of the material while the high elongation-to-156 break elastomer coated implant had no cracking. 157
Crosslink density was controlled by adjusting both molecular weight of the prepolymer and 158 the amount of crosslinker used to prepare the elastomer. We created a series of elastomers using 159 PGCL of different molecular weights (e.g., 20,000 and 100,000 g/mol) with various amounts of 160 HDI crosslinker (e.g., ratio of elastomer to HDI of 20:1 to 20:4 by weight). Mechanical 161 measurements demonstrated that higher molecular weight prepolymers with optimized cross-link 162 density yielded elastomers with high elongation-to-break of 300% or greater (Supplemental Table  163 1). 164
Elastomers were further characterized to understand the contribution of plastic 165 deformation to the material elongation. We hypothesized that an elastomer with high plastic 166
deformation would lead to irreversible stretching during crimping, resulting in incomplete recovery 167 of the elastomer-coated implant. We measured plastic deformation using cyclic mechanical 168 loading. In this process, tensile testing was performed on dogbone-shaped samples for five 169
consecutive cycles up to 300% strain, and the permanent deformation was defined as the residual 170 strain at the beginning of the fifth cycle. Crosslink density and molecular weight were optimized 171 to ensure less than 25% permanent deformation. 172
In summary, we created fully resorbable elastomers, leveraging well-characterized, 173 biocompatible building blocks. We were able to "lock" the intersection points of fibers on a base 174 braid, by coating the braid with a thermoset elastomer. The coating is intended to restrain but not 175 restrict pivoting of the fiber struts (if the coating is too restrictive, then the fiber struts would bend, 176 potentially leading to buckling, deformation, or poor recovery). To optimize mechanical properties, 177
we incorporated polymer branching along with modulation of cross-link density and molecular 178 weight. We selected an optimized, branched PGCL elastomer with greater than 300% elongation-179
to-break and less than 25% permanent deformation for further study. Doing so yielded a strong 180 implant from "weak" materials. 181
Our composite structure created an implant with unique properties relative to current 182 polymeric resorbable stents that utilize monolithic, highly-crystalline, oriented, extruded polymer 183 tubes. These devices include Remedy (Kyoto Medical), Bioresorbable Vascular System (Abbott), 184
and Desolve (Elixir) stents. Although the latter two devices have good radial strength, they have 185 minimal COF and therefore are not self-expanding. This data highlights the uniqueness of the 186 design created herein. 187
Acute mechanical properties 188
The optimized PGCL elastomer was applied to the base braid and cured, creating a 189 polyester with urethane crosslinks (polyester/polyurethane) as shown in Figure 2F . properties, exhibiting an RRF = 712 ± 45 mmHg and COF = 151 ± 5 mmHg. In contrast, the same 194 braid without an elastomer coating had mechanical properties of RRF = 90 ± 5 mmHg and COF 195 = 28 ± 3 mmHg ( Figure 1B) . These results demonstrate that the elastomer coating substantially 196
improved the mechanical properties of the base braid, achieving mechanical properties similar to 197 benchmark self-expanding metallic stents but utilizing fully resorbable materials ( Figure 1B ). 198
Radial force testing under multiple cycles indicated that at a 4.5 mm diameter, the maximum acute 199 plastic deformation response decreased the RRF by ~ 25% while the COF remains essentially 200 unchanged. Over a range of target vessel diameters, the RRF is relatively constant with values 201 between 890 ± 54 to 823 ± 61 mmHg while the COF ranges from 243± 9 to 118 ± 7 mmHg 202 (Supplemental Figure 1) . These results are particularly remarkable when considering that the 203 mechanical properties of the starting materials for the bioresorbable were considerably weaker 204 than those used in metal stents. Application of the optimized elastomeric coating had an additional 205 benefit -an acute recovery greater than 95% of the manufactured diameter was demonstrated, 206
overcoming the acute stress relaxation of the base braid during crimping and deployment. To 207 avoid the long-term effects of prolonged duration in a crimped state on the ability of an implant to 208 self-expand, our implants will be packaged in an uncrimped state along with a delivery system 209 that contains a mechanism to crimp the implant into a catheter immediately prior to its use. 210
Chronic properties and vascular biocompatibility
Beyond the acute phase, a critical characteristic of any self-expanding, resorbable implant 212 is the biocompatibility throughout its resorption. The materials resorb via a hydrolytic resorption 213 mechanism through random scission of the ester linkage in the polymer's backbone as shown in 214
Supplemental Figure 2 . The major resorption products from this hydrolytic process are the small 215 molecules lactic acid, glycolic acid, and 6-hydroxyhexanoic acid from the PLA, PGA and PCL 216 polymer segments, respectively [19, 20]. These small molecules or further degradants of these 217 small molecules then enter the tricarboxylic acid cycle and are eventually eliminated from the 218 body as carbon dioxide and water. The urethane/urea segments make up less than 4% by weight 219 of the implant and degrade via an oxidative mechanism giving rise to the small molecule 220 hexamethylenediamine (HDA) [21] . HDA is then eliminated from the body via urine [22, 23] . with our in vivo results. Extrapolating from in vitro results, the anticipated resorption times for the 257 75:25/PGCL and the 75:25/PLCL were 6 -7 months and 9 -10 months, respectively. 258
When implanted in swine, all vessels with the 75:25/PGCL and 75:25/PLCL devices 259 remained patent by angiography at 30, 90, and 180 days. Additionally, all vessels were fully 260 endothelialized by 30 days. In the 75:25/PGCL group, significant in vivo resorption had occurred 261 at 90 days (consistent with in vitro predictions), as evidenced histologically by decreasing size of 262 implant struts and penetration of cells into the device remnants over time. This resorption 263 coincided with a strong inflammatory response with the presence of granuloma. By 180 days, this 264 inflammatory response had partially subsided, but we deemed the device incompatible based on 265 the 90 day response. Examination of the slowest degrading 75:25/PLCL device revealed excellent 266 histological compatibility ( Figure 6A ). Only a minimal-mild inflammation was observed at 30 and 267 90 days; disruptions of the internal elastic lamina (IEL) and the external elastic lamina (EEL) were 268 rare. The overall stenosis observed in this device was mild and considered to be acceptable 269
(average diameter stenosis measured by angiography of 9.1 ± 2.7% and 7.4 ± 5.6% at 90 and 270 180 days, respectively). Minimal resorption was observed at 90 days, though occasional cell 271
infiltration was observed histologically in the implant struts indicating resorption had initiated. 272
Significant resorption occurred at 180 days, with only small remnant particles of the device 273 remaining. In contrast to the PGCL devices, this resorption was accompanied by a modest 274 amount of inflammation and minimal IEL/EEL disruption. These results suggest excellent 275 compatibility of the 75:25/PLCL bioresorbable implant throughout the resorption process. Detailed 276 quantitative assessments of the implantation and semi-quantitative comparison of injury, 277 inflammation, and fibrin between groups and timepoints are provided in Supplemental Table 2 . 278
Overall, the three implant designs tested demonstrated distinct resorption profiles. These 279 results indicate the importance of the resorption properties of the device, both the base braid and 280 the elastomer, on its vascular compatibility. These results are consistent with others who have 281 demonstrated the importance of controlling the rate of implant resorption within the initial critical 282 vessel healing period [24] . 283
Addressing elastic recoil 284
It has been previously hypothesized that a bioabsorbable stent should not lose mechanical 285
properties until the vessel has fully remodeled to avoid chronic recoil (estimated time ~90 days). 286
While the 75:25/PLCL device demonstrated excellent compatibility in animals, bench data 287 indicated that this device exhibited minimal COF after 28 days (Supplemental Figure 3) . In an 288 effort to extend the retention of mechanical properties, an additional variant of the implant was 289 studied that used 85:15 L-PLGA fiber as the base braid material with a PLCL elastomer coating, 290 85:15/PLCL, and were able to demonstrate measurable properties out to 3 months (Supplemental 291 Figure 3 ). Fatigue testing on this design showed mechanical integrity out to 22 weeks 292 (Supplemental Figure 4) . 293
We conducted an additional pre-clinical study to examine the biocompatibility of the 294 75:25/PLCL and 85:15/PLCL devices throughout their full resorption. In this study, we utilized the 295 femoral and profunda vessels in an ovine model to assess compatibility in a second species and 296 vessel bed. The ovine model was selected because it provides longer and larger vessels in the 297 legs, representing a closer anatomy to human superficial femoral arteries [25] . In addition, the 298 ovine model has a coagulation and fibrinolytic system with more similarities to that of humans 299 than other species [25] . In this model, the majority of the base braid in the 75:25/PLCL device 300 was absorbed by 6 months, similar to the findings from the swine model. As expected, the 301 85:15/PLCL base braid demonstrated a longer resorption time compared to the 75:25/PLCL, with 302 full resorption by 18 months. In both designs, mild to moderate amount of inflammation without 303 granuloma was present, minimal vessel injury was observed, and the EEL was fully intact at all 304 time points, indicating again acceptable vascular compatibility from implantation through 305 resorption ( Figure 6B and Supplemental Table 3 ). The 85:15/PLCL optimized implant design is 306 biocompatible and addresses elastic recoil of the blood vessel by maintaining mechanical 307
properties for 3 months. 308
In summary, we have developed a unique composite design to create a bioresorbable, 309
self-expanding implant consisting of an elastomer coating that can be applied to a base braid to 310 provide mechanical strength and to resist stress relaxation. Leveraging this composite design we 311
have created an implant with acute properties similar to metal benchmark devices from "weak" 312 polymer materials. The self-expansion and mechanical properties allow the implant to be 313 delivered into and conform to various cavities within the body. 314
This composite device that is bioresorbable and self-expanding meets all the design 315 requirements for vessels undergoing significant motion: it is strong, elastic, and biocompatible. 316
Given that pre-clinical safety of the device has been established, the next step is to examine the 317 device in human clinical studies. In particular, the chronic recoil performance of the implant in 318 calcified lesions could be a limitation and needs to be evaluated. This device has the potential to 319 be the first bioresorbable, fully self-expanding implant, affording patients an alternative treatment 320 option. 321
The applicability of the composite strategy described herein goes beyond the specific 322 bioresorbable device described herein. Bioresorbable implants eliminate any permanent nidi for 323 chronic irritation. The coupling of strong materials with elastomeric ones provides an approach to 324 create bioresorbable constructs that mimic the properties of native soft tissue. This approach has 325 tremendous potential in the development of new implants to treat diseases of soft tissue across 326 the body. 327 
